This activity will address the burden of major bleeding for patients on oral anticoagulants and the health-systems that treat them. Principles of reversal agent stewardship will be shared along with methods for creating or supplementing institutional policies with prescribers and other key stakeholders. Learners will be exposed to best practices in dosing and administration in special patient populations, along with variables that may influence restarting anticoagulation after a major bleeding event.
The target audience for this activity includes pharmacists. At the completion of this activity, the participant will be able to:
- Describe risk stratification and the clinical burden of acute major bleeding.
- Discuss the importance of involving the multidisciplinary team in institutional policy development for reversal agents.
- Examine administration, dosing, and monitoring of anticoagulant reversal agents in special populations.
- Outline variables to consider when restarting anticoagulation after an acute major bleeding event.
Tyree H. Kiser, Pharm.D., FCCM, FCCP, BCPS
Professor, Department of Clinical Pharmacy
University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences
Anschutz Medical Campus
Critical Care Pharmacy Specialist, University of Colorado Hospital
Jessica Rimsans, PharmD, BCPS
Clinical Pharmacy Specialist
Hemostatic and Antithrombotic Stewardship
Brigham and Women’s Hospital, Department of Pharmacy Services
John Fanikos, RPh, MBA
Executive Director of Pharmacy Services
Brigham and Women’s Hospital
Release Date: December 7, 2020
Expiration Date: December 31, 2021
Pro CE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-20-501-H01-P has been assigned to this home study knowledge-based activity. This activity is approved for 1.5 contact hours (0.15 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of an evaluation and post-test with a score of 70% or higher is required to receive CE credit. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Mr. Fanikos has received honorarium as a speaker for Portola, and honorarium as a consultant for Boehringer-Ingelheim, Pacira, and Pfizer. Dr. Kiser has received honorarium as an advisory board member for Portola, and research grant funding as a research investigator for CSL Behring. Dr. Rimsans has no relevant commercial or financial relationships to disclose.
This activity is supported by an educational grant from Portola Pharmaceuticals, Inc.
The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.